None

Eculizumab (Eculizumab) is the first and only drug approved to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). However, the safety of eculizumab based on long-term pharmacovigilance is unknown. Continued understanding and implementation of risk mitigation options are critical to minimizing the risk of meningococcal and other Neisseria infections in patients receiving eculizumab.

Eculizumab specifically binds to the terminal complement component5 or C5 and plays a role in the late stage of the complement cascade. When activated, C5 is involved in activating host cells, thereby attracting pro-inflammatory immune cells, while also damaging cells by triggering pore formation. By inhibiting the complement cascade at this point, the normal disease-preventive functions of the proximal complement system are largely preserved, while the inflammation-promoting and cell-destroying properties of C5 are hindered. The metabolism of eculizumab is thought to occur via lysosomal enzymes, and its distribution volume in humans is close to that of plasma.

The patented drug Eculizumab has been launched in China and is covered by medical insurance. Reimbursement is limited to eligible patients. The specification is The price of each box of 300mg (30ml) may be more than 3,000 yuan. This drug may be sold in domestic hospitals and other places. It is understood that the price of each box of the original Eculizumab drug sold overseas is more than 6,000 US dollars (the price may fluctuate due to the exchange rate). The ingredients of the original drug sold at home and abroad are basically the same, and the price of the original drug is still relatively expensive. There are currently no generic versions of eculizumab available on the market.